Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT02729441 | Perindopril vs Ramipril for Persistence in MAU Reduction Study | PHASE3 | COMPLETED | 23 | — | — | Apr 1, 2010 | Dec 1, 2012 | Apr 6, 2016 | 1 | Canada |
spot urine samples
24 hour, day, and night systolic and diastolic blood pressure
| Arm | Type | Description |
|---|---|---|
| Ramipril | ACTIVE_COMPARATOR | Maximal recommended dose of ramipril "Altace®" (10 mg/d) given as an active comparator for 12 week. |
| Perindopril | EXPERIMENTAL | Perindopril "Coversyl®" at maximal recommended dose (8 mg/d) as experimental therapy for 12 weeks. |
| Name | Type | Description |
|---|---|---|
| ramipril | DRUG | Comparison of two renin angiotensin aldosterone inhibitors |
| perindopril | DRUG | Comparison of two renin angiotensin aldosterone inhibitors |
Inclusion Criteria: * Type 2 Diabetes, * stable therapy with an ACEi or ARB for 8 weeks prior to screening period * blood pressure controlled to \< 130/80 mmHg Exclusion Criteria: * Pregnancy, * dual therapy with ACEi and ARB 8 weeks prior to screening * history of cough with ACEi * hypersensitiv...